Characterizing fatigue associated with sunitinib and its impact on health-related quality of life in patients with metastatic renal cell carcinoma Academic Article uri icon

Overview

MeSH Major

  • Antineoplastic Agents
  • Carcinoma, Renal Cell
  • Fatigue
  • Indoles
  • Kidney Neoplasms
  • Pyrroles

abstract

  • Patients reported worse fatigue during the first sunitinib cycle. However, in subsequent consecutive cycles, less fatigue was reported with no statistically significant worsening. CTCAE fatigue assessment may not fully capture patient treatment experience.

publication date

  • June 15, 2014

Research

keywords

  • Academic Article

Identity

Language

  • eng

PubMed Central ID

  • PMC4231253

Digital Object Identifier (DOI)

  • 10.1002/cncr.28660

PubMed ID

  • 24634003

Additional Document Info

start page

  • 1871

end page

  • 80

volume

  • 120

number

  • 12